Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus plus glucocorticoid ± immunosuppressant in active lupus nephritis with interstitial lesions
ChiCTR2600124863Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sirolimus in lupus nephritis (LN), sponsored by Peking University First Hospital. Primary endpoint: Primary efficacy renal response. Started May 2026; status: recruiting.
02
Drugs
sirolimus
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR2600124863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124863.